KTJ Medical Technology 2025 Annual Report: Revenue RMB 490 Million, Up 4.18%; Dental Implant & Components Segment Revenue Down 12%

Source: Kangtaijian 2025 Annual Report

DentalGoodNews｜On April 29, 2026, KTJ Medical Technology Co., Ltd. (hereinafter referred to as "KTJ") released its 2025 annual report. During the reporting period, the company achieved operating revenue of RMB 490 million, a year-on-year increase of 4.18%; net profit attributable to shareholders of the parent company was RMB 31.268 million, a year-on-year decrease of 38.62%.

According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), KTJ was approved for listing on the National Equities Exchange and Quotations (NEEQ) in September 2025, with operating revenue of RMB 470 million in 2024, a year-on-year increase of 20.25%. Entering 2025, the company's revenue growth slowed, and profit margins contracted. After deducting non-recurring gains and losses, the net profit attributable to shareholders of the parent company was RMB 26.176 million, a year-on-year decrease of 50.19%.

Source: Kangtaijian 2025 Annual Report

Domestic and overseas business performance showed divergence. In 2025, KTJ's domestic sales revenue was RMB 355 million, a year-on-year decrease of 8.10%, with gross margin dropping from 51.49% in the same period last year to 44.15%. Overseas sales revenue reached RMB 133 million, a year-on-year increase of 61.46%, accounting for 27.32% of main business revenue, up from 17.63%.

Source: Kangtaijian 2025 Annual Report

By product line, the implant denture and accessories segment generated revenue of RMB 132 million, a year-on-year decrease of 12.24%. Additionally, the company stated that the main all-ceramic products for implant dentures participated in competitive price-linked procurement, leading to a decline in selling prices and driving price adjustments for other products. The gross margin for this business decreased by 14.93 percentage points year-on-year. During the same period, revenue from fixed dentures increased by 7.25%, while revenue from removable dentures and orthodontic products grew by 19.63% and 16.57%, respectively.

Source: Kangtaijian 2025 Annual Report

In terms of profit, the company's overall gross margin in 2025 was 43.39%, a year-on-year decrease of 2.82 percentage points. Credit impairment losses amounted to RMB 24.9508 million, an increase of 160.29% compared to RMB 9.5859 million in the same period last year, primarily due to specific provisions made for accounts receivable. Furthermore, investment income turned to a loss, with a loss of RMB 1.9334 million in the current period, mainly affected by investment losses from the associate company Shujie Medical Technology.

Source: Kangtaijian 2025 Annual Report

Regarding talent structure, as of the end of 2025, KTJ had 1,610 employees, a decrease of 131 from the beginning of the period. Among them, production staff decreased by 93, sales staff decreased by 31, and R&D staff remained at 106. The company's R&D expenses in 2025 were RMB 20.4333 million, with an R&D intensity of 4.17%.

Source: Kangtaijian 2025 Annual Report

In terms of asset quality, the book value of accounts receivable at the end of the period was RMB 164 million, accounting for 28.04% of total assets. According to previous reports by DGN, the company has submitted IPO guidance filing materials for the Beijing Stock Exchange (BSE) and is currently in the guidance period.